查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008305

骨髓恶性肿瘤市场：2026-2032年全球市场预测（按疾病类型、治疗类型、治疗方法分类、治疗阶段、患者年龄层、最终用户和分销管道划分）

Hematological Malignancies Market by Disease Type, Treatment Type, Therapy Class, Line Of Therapy, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，骨髓恶性肿瘤市场价值将达到 185.8 亿美元，到 2026 年将成长至 205 亿美元，到 2032 年将达到 366.5 亿美元，年复合成长率为 10.18%。

主要市场统计数据
基准年 2025 185.8亿美元
预计年份：2026年 205亿美元
预测年份 2032 366.5亿美元
复合年增长率 (%) 10.18%

这是一份简明扼要、权威详尽的血液恶性肿瘤临床和商业性趋势概述，为研发和治疗路径中的策略决策提供指导。

骨髓恶性肿瘤涵盖了血液肿瘤领域一个复杂且不断发展的范畴，为临床医生、研究人员和相关人员带来了许多挑战。本执行摘要整合了治疗研发、医疗服务流程和商业化管道的关键趋势、结构性转变和实际应用，旨在为那些必须将科学进展转化为切实可行的临床项目和永续经营模式的领导者提供简洁而全面的指南。

细胞工程、精准医疗和综合护理服务的突破如何重新定义血液肿瘤治疗的预期和临床路径。

随着生物学、治疗工程和医疗服务模式的进步不断融合，骨髓恶性肿瘤领域正经历着一场变革。精准医疗的原则正从单一基因标靶扩展到细胞和免疫系统的调控，从而改变临床试验的设计方式和长期疗效的评估方法。基因修饰细胞疗法等创新技术正在重新定义人们对持续疗效的预期，而抗体工程和小分子抑制剂的不断改进则持续提升了治疗的耐受性和门诊治疗的可行性。

了解不断变化的贸易关税如何影响血液疾病治疗供应链的韧性、筹资策略和业务永续营运。

关税和国际贸易政策的变化会对血液疾病领域药物研发和临床治疗的供应链产生重大影响。近期关税调整给依赖跨境采购活性药物成分、先进生物製药组件以及细胞治疗生产专用设备的製造商和医疗服务提供者带来了新的挑战。因此，采购团队和契约製造必须在不影响产品品质或合规性的前提下，重新评估供应商的应对能力和总到岸成本。

一个多层细分框架，揭示了疾病亚型、治疗方法和护理路径如何决定临床开发重点和准入策略。

一个精细的细分框架揭示了治疗创新如何与患者需求、医疗环境和分销基础设施相互作用。依疾病类型分析市场发现，骨髓发育不良症候群和骨髓增殖性肿瘤之间存在异质性，每种疾病组都包含具有临床意义的亚型，这些亚型决定了独特的诊断和治疗路径。例如，急性白血病和慢性白血病需要不同的诱导和强化治疗策略。同时，淋巴瘤和骨髓发育不良症候群内部的多样性也需要针对亚型进行生物标记评估和治疗顺序安排。

美洲、欧洲、中东和非洲以及亚太地区的区域基础设施、监管多样性和医疗保健资金筹措如何影响先进血液疾病疗法的采用和取得？

区域趋势对研究重点、基础设施建设以及先进血液疾病疗法的应用具有至关重要的影响。在美洲，健全的临床试验体系和集中且高品质的医疗中心推动了复杂治疗方法的早期应用。这得益于整合的支付方-医疗服务提供方机制以及强大的创投生态系统，后者促进了转化研究的发展。这种环境在推动快速概念验证试验的同时，也要求建立严谨的证据体系，以满足不同支付方的要求，并确保在都市区和社区环境中永续获得治疗。

为什么那些整合了深厚的科学差异化、卓越的营运能力和策略伙伴关係的公司，能够在为患者提供血液疾病治疗方面获得决定性优势？

骨髓恶性肿瘤领域各公司之间的竞争格局反映了它们在药物发现、转化科学和可扩展生产方面的能力差异。主要企业将强大的转化产品线与监管机构的合作策略相结合，强调严格的安全性监测和长期追踪。同时，新兴生物技术公司通常专注于差异化的作用机制和平台技术，以实现跨适应症的模组化开发。合约开发和生产组织（CDMO）正发挥日益重要的策略作用，为小规模申办者应对复杂生技药品和细胞疗法的生产挑战提供支持。

为领导者提供切实可行的策略措施，以加强生产韧性、证据一致性和交付模式，从而确保血液疾病治疗的永续取得。

产业领导者可以采取切实可行的措施来强化产品线、降低营运风险并加速患者获得治疗。首先，应优先投资于提升生产韧性，具体措施包括供应商多元化、检验国内外生物製药组件合作伙伴的资质，以及采用灵活的生产方式，以便随时切换治疗方法和适应症。这将有助于减轻国际贸易变化的影响，并增强临床项目和商业性供应链的连续性。

透过整合临床文献、咨询专家和进行操作检验，我们采用透明、多方面的调查方法，得出可靠的策略结论。

本分析基于严谨的多方面调查方法，旨在确保其可靠性、可重复性和对决策者的相关性。该方法整合了来自临床、生产和支付方领域关键意见领袖（KOL）的定性见解，并对同行评审的临床文献、监管指导文件和临床实验指南进行了系统性回顾。在条件允许的情况下，我们还使用了检验验证的真实世界数据和註册研究结果，以更好地理解临床趋势，并为营运方面的考虑（例如研究中心准备情况和患者诊疗路径）提供资讯。

证据整合与策略重点：展示临床创新、营运韧性和个人化市场方法如何协调一致，从而对患者产生影响。

总之，骨髓恶性肿瘤领域的特征是科学发展日新月异，研发、生产和进入途径日益复杂。细胞疗法、先进的免疫疗法和标靶治疗正在重塑临床预期，而供应链和政策趋势则要求我们更加谨慎地运作。按疾病亚型、治疗方法类型、治疗线数、患者年龄层、医疗服务环境和分销管道进行细分，可以揭示临床创新在哪些方面能够最有效地转化为患者获益和商业性可行性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章骨髓恶性肿瘤市场：依疾病类型划分

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 慢性骨髓性白血病
  • 淋巴瘤
    • 何杰金氏淋巴瘤
      • 经典类型
      • 结节性淋巴细胞丰富型
    • 非何杰金氏淋巴瘤
      • B细胞
      • T细胞
  • 多发性骨髓瘤
  • 骨髓发育不良症候群
    • 难治性贫血
    • 难治性贫血伴随原始细胞过多。
    • 伴随环状铁粒幼细胞的难治性贫血
    • 难治性血球减少症伴随多系统发育不良
  • 骨髓增生性肿瘤
    • 原发性血小板增多症
    • 骨髓纤维化
    • 真性红血球增多症

第九章：骨髓恶性肿瘤市场（依治疗类型划分）

  • 化疗
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
  • 干细胞移植
    • 同种
    • 自有住房
  • 标靶治疗
    • 免疫调节药物
      • Lenalidomide
      • Thalidomide
    • 单株抗体
      • 抗CD20
      • 抗CD38
    • 蛋白酶体抑制剂
      • Bortezomib
      • Carfilzomib
    • 蛋白酪氨酸激酶抑制剂
      • BCR-ABL抑制剂
      • BTK抑制剂

第十章骨髓恶性肿瘤市场依治疗方法划分

  • 细胞疗法
    • CAR-T细胞疗法
    • 树突细胞疫苗
  • 免疫调节药物
    • Pomalidomide
    • Thalidomide
  • 单株抗体
    • 抗CD20
    • 抗CD38
  • 蛋白酶体抑制剂
    • Bortezomib
    • Carfilzomib
  • 小分子抑制剂
    • 蛋白酪氨酸激酶抑制剂
    • 维内托克拉克斯

第十一章骨髓恶性肿瘤市场（依治疗阶段划分）

  • 一线治疗
  • 维持治疗
  • 第二行
  • 从第三行开始

第十二章 依病患年龄组别分類的骨髓恶性肿瘤市场

  • 成人版
  • 老年人
  • 儿童

第十三章骨髓恶性肿瘤市场：依最终用户划分

  • 门诊部
  • 医院
  • 研究机构
  • 专科诊所

第十四章骨髓恶性肿瘤市场：依通路划分

  • 直接购买
  • 医院药房
  • 网路药房
  • 零售药房

第十五章骨髓恶性肿瘤市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章骨髓恶性肿瘤市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章骨髓恶性肿瘤市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国骨髓恶性肿瘤市场

第十九章：中国骨髓恶性肿瘤市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Adaptimmune Limited
  • Adcendo ApS
  • Amgen Inc.
  • Artiva Biotherapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Dren Bio, Inc.
  • F. Hoffmann-La Roche AG
  • Geron Corporation
  • GlaxoSmithKline PLC
  • Harpoon Therapeutics, Inc.
  • Immune-Onc Therapeutics, Inc.
  • Interius BioTherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Kirilys Therapeutics, Inc.
  • Kymera Therapeutics
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Moleculin Biotech, Inc.
  • NovalGen Ltd.
  • Novartis AG
  • Oncoternal
  • Pfizer Inc.
  • Prelude Therapeutics Incorporated
  • Reverie Labs Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • TG Therapeutics, Inc.
  • Tvardi Therapeutics, Inc.
Product Code: MRR-C002B1C994F0

The Hematological Malignancies Market was valued at USD 18.58 billion in 2025 and is projected to grow to USD 20.50 billion in 2026, with a CAGR of 10.18%, reaching USD 36.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.58 billion
Estimated Year [2026] USD 20.50 billion
Forecast Year [2032] USD 36.65 billion
CAGR (%) 10.18%

A concise and authoritative orientation to the evolving clinical and commercial landscape of blood cancers to guide strategic decision-making across development and care pathways

Hematological malignancies encompass a complex and evolving landscape of blood cancers that challenge clinicians, researchers, and commercial stakeholders. This executive summary synthesizes core trends, structural shifts, and pragmatic implications across therapeutic development, care delivery pathways, and commercialization channels. The intent is to provide a concise yet comprehensive orientation for leaders who must translate scientific progress into viable clinical programs and sustainable business models.

The content that follows distills emerging therapeutic paradigms, regulatory and policy influences, patient demographic dynamics, and ecosystem-level forces shaping research priorities and healthcare utilization. It frames the principal modalities now driving clinical progress, including cellular therapies, targeted agents, and refined immunomodulatory strategies, while acknowledging the persistent role of conventional modalities such as chemotherapy and stem cell transplantation. By integrating clinical nuance with commercialization realities, this introduction equips readers to interpret subsequent sections that examine strategic segmentation, tariff impacts, regional patterns, and recommended actions for industry leaders.

Throughout, the narrative emphasizes clarity and applicability; transitional commentary guides readers from high-level context into detailed segmentation and operational recommendations. The goal is to enable clinicians, portfolio managers, payers, and policy advisors to rapidly identify leverage points, anticipate shifts in treatment paradigms, and position resources to capture clinical and commercial value across the hematology oncology continuum.

How breakthroughs in cellular engineering, precision therapeutics, and integrated care delivery are redefining treatment expectations and clinical pathways in blood cancers

The landscape of hematological malignancies is undergoing transformative shifts driven by converging advances in biology, therapeutic engineering, and care delivery models. Precision medicine principles now extend beyond single-gene targets to include cellular and immune system modulation, altering how trials are designed and how long-term outcomes are measured. Innovations such as engineered cell therapies have reframed expectations for durable responses, while incremental refinements in antibody engineering and small molecule inhibitors continue to improve tolerability and outpatient feasibility.

Concurrently, regulatory frameworks and payer assessment methodologies are adapting to evidence generated from novel trial designs and real-world data, which accelerates pathways for therapies addressing high unmet need but also raises the bar for long-term safety and value demonstration. Clinical practice patterns are shifting as multidisciplinary care teams integrate advanced therapeutics alongside established modalities like stem cell transplantation; this creates new demand for specialized centers and coordinated care pathways. Moreover, the maturation of supportive care and diagnostic tools enhances treatment selection and monitoring, enabling more personalized sequencing across lines of therapy.

Taken together, these transformative shifts create both opportunities and responsibilities for stakeholders: to optimize clinical benefit, to innovate around access and delivery, and to align investment priorities with modalities that promise meaningful patient outcomes while remaining operationally feasible in diverse healthcare settings.

Understanding how evolving trade tariffs are reshaping supply chain resilience, procurement strategies, and operational continuity for hematology therapeutics

Policy changes related to tariffs and international trade can exert meaningful influence on the supply chains that underpin hematology drug development and clinical care. Recent tariff adjustments have introduced a new layer of complexity for manufacturers and providers who rely on cross-border sourcing for active pharmaceutical ingredients, advanced biologic components, and specialized equipment used in cellular therapy manufacturing. As a consequence, procurement teams and contract manufacturers must reassess supplier resilience and total landed cost without compromising quality or regulatory compliance.

In parallel, clinical sites and research institutions that import laboratory reagents, diagnostic kits, and infusion-related disposables face increased administrative overhead associated with customs, compliance checks, and logistical delays. These operational frictions can extend timelines for trial enrollment and routine patient care, prompting sponsors and academic centers to strengthen domestic sourcing strategies and to negotiate more robust contingency arrangements with logistics partners. Importantly, the effects are uneven across therapeutic categories; products that depend on cold chain logistics or on modular manufacturing components are particularly susceptible to tariff-driven disruption.

Thus, organizations engaged in therapeutic development and care delivery must systematically map their international supplier networks, quantify operational risk, and incorporate tariff considerations into procurement policy and strategic planning. By doing so, stakeholders can mitigate supply chain shocks, preserve trial continuity, and maintain patient access to advanced therapies even as trade policies evolve.

A layered segmentation framework revealing how disease subtypes, therapeutic modalities, and care pathways determine clinical development priorities and access strategies

A nuanced segmentation framework clarifies how therapeutic innovation intersects with patient need, care settings, and distribution infrastructures. When the market is parsed by disease type, the heterogeneity across leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms becomes apparent, and each disease grouping contains clinically meaningful subtypes that drive unique diagnostic and therapeutic pathways. For example, acute and chronic leukemias demand distinct induction and consolidation strategies, while the diversity within lymphomas and myelodysplastic syndromes necessitates subtype-specific biomarker assessment and treatment sequencing.

Evaluating treatment type reveals parallel dynamics: chemotherapy remains a foundational modality in many indications, but immunotherapy, stem cell transplantation, and targeted therapies introduce alternative mechanisms of action and novel care requirements. Subclassifications within immunotherapy and targeted agents further influence clinical development priorities and site readiness, since therapies such as engineered cellular products and monoclonal antibodies require specialized infusion infrastructure and monitoring capabilities. Looking through the lens of therapy class surfaces overlapping categories-cellular therapies, immunomodulatory agents, monoclonal antibodies, proteasome inhibitors, and small molecule inhibitors-each with divergent manufacturing complexities and clinical monitoring demands.

Line of therapy segmentation underscores how product positioning evolves across patient journeys from first-line to maintenance and beyond, influencing evidence generation strategies and commercial access planning. Patient age group segmentation highlights differential tolerability and treatment selection for pediatric, adult, and geriatric populations, with implications for dosing, supportive care, and trial design. Finally, end user and distribution channel distinctions-spanning hospitals, ambulatory centers, specialty clinics, and a mix of procurement pathways-shape reimbursement interactions and channel-specific adoption curves. Together, this layered segmentation informs targeted development, launch sequencing, and operational readiness decisions.

How regional infrastructure, regulatory diversity, and healthcare financing in the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption and access for advanced hematology therapies

Regional dynamics exert a decisive influence on research priorities, infrastructure development, and adoption of advanced hematology therapies. In the Americas, robust clinical trial ecosystems and concentrated centers of excellence have driven early adoption of complex modalities, supported by integrated payer-provider arrangements and a strong venture ecosystem that underwrites translational initiatives. This environment encourages rapid proof-of-concept testing but also demands rigorous evidence generation to satisfy diverse payer requirements and to secure sustainable access across both urban and community settings.

Across Europe, the Middle East & Africa, health systems exhibit significant heterogeneity in regulatory approaches, reimbursement mechanisms, and care delivery capacity. Fragmentation within this broad region creates both challenges and opportunities: centralized regulatory harmonization initiatives can streamline approvals, while variable infrastructure and workforce capacity necessitate adaptable deployment models for complex therapies. Stakeholders must therefore calibrate clinical and commercial strategies to regional reimbursement norms and to the distribution of specialized treatment centers.

In the Asia-Pacific region, rapid investment in biomanufacturing, coupled with growing clinical trial participation and national strategies to expand access to innovative medicines, is reshaping global development timelines. However, differing regulatory expectations and local clinical practice patterns require sponsors to develop region-specific evidence and to engage early with local stakeholders. Across all regions, aligning clinical development, manufacturing scale-up, and market access planning with local infrastructure realities is essential to translate scientific advances into patient benefit.

Why companies that integrate deep scientific differentiation with operational excellence and strategic partnerships gain decisive advantages in bringing hematology therapies to patients

Competitive dynamics among companies involved in hematological malignancies reflect a spectrum of capabilities in discovery, translational science, and scalable manufacturing. Leading developers combine strong translational pipelines with regulatory engagement strategies that emphasize robust safety monitoring and long-term follow-up, while emerging biotechnology firms often concentrate on differentiated mechanisms of action or on platform technologies that enable modular development across indications. Contract development and manufacturing organizations play an increasingly strategic role, supporting smaller sponsors through complex biologics and cell therapy production challenges.

Commercial organizations must navigate an environment where scientific differentiation coexists with operational execution risk; success depends not only on clinical efficacy but also on the ability to secure reliable supply chains, to negotiate coverage with payers, and to support treating centers with training and logistics. Partnerships and alliances frequently bridge capability gaps-whether to expand geographic reach, to integrate companion diagnostics, or to co-develop delivery models that reduce the burden on hospitals. Investors and corporate partners increasingly value demonstrable operational readiness alongside clinical proof points, recognizing that durable commercial performance requires end-to-end excellence from discovery through patient support programs.

Therefore, companies that align scientific innovation with comprehensive operational strategies and collaborative commercialization models are best positioned to translate breakthroughs into widely available clinical options, while maintaining compliance with regulatory and payer expectations.

Practical strategic moves for leaders to strengthen manufacturing resilience, evidence alignment, and delivery models to secure sustainable access for hematology treatments

Industry leaders can take specific, actionable steps to fortify pipelines, reduce operational risk, and accelerate patient access. First, prioritize investments in manufacturing resilience by diversifying suppliers, validating domestic and regional partners for critical biologic components, and adopting flexible manufacturing approaches that can switch between modalities and indications. This reduces exposure to international trade shifts and strengthens continuity for clinical programs and commercial supply.

Second, design evidence generation plans that anticipate payer and regulatory expectations by combining randomized data with real-world evidence and health economic modeling. Early engagement with regulators and payers helps align trial endpoints and follow-up protocols with reimbursement criteria, increasing the likelihood of post-launch coverage. Third, build scalable delivery models in partnership with treatment centers, investing in workforce training, center accreditation programs, and shared-service consortia for high-cost therapies to improve geographic access while managing per-patient delivery costs.

Finally, cultivate cross-sector collaborations that accelerate diagnostic development, harmonize data standards, and support value-based contracting pilots. By integrating strategic procurement, regulatory foresight, and delivery innovation into corporate planning, organizations can mitigate systemic risks, enhance adoption rates, and ensure that scientific advancements translate into durable patient benefit.

A transparent, multi-source research methodology combining clinical literature synthesis, expert consultation, and operational validation to support robust strategic conclusions

This analysis derives from a rigorous, multi-source research methodology designed to ensure reliability, reproducibility, and relevance to decision-makers. The approach integrates a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and treatment guidelines, combined with qualitative inputs from key opinion leaders across clinical, manufacturing, and payer domains. Where available, validated real-world data and registry insights were used to contextualize clinical trends and to inform operational considerations such as site readiness and patient pathways.

Analysts cross-validated findings by triangulating evidence from clinical trial registries, manufacturing and supply chain reports, and regulatory precedent, with emphasis on synthesis rather than raw forecasting. The methodology prioritized transparency in the classification schema and in the criteria applied for therapeutic and regional segmentation, ensuring that conclusions reflect clinically relevant distinctions and practical deployment realities. Where expert opinion was incorporated, contributors were selected for domain-specific expertise and geographic representation to avoid single-market bias.

All analytic steps adhered to recognized standards for secondary research and qualitative synthesis, with documentation of inclusion criteria, data sources, and limitations provided in the full research appendices. This disciplined approach underpins the recommendations and insights presented, enabling readers to judge applicability to their strategic contexts and to request additional granularity as needed.

Synthesis of evidence and strategic priorities showing how clinical innovation, operational resilience, and tailored market approaches must align to deliver patient impact

In conclusion, the hematological malignancies landscape is defined by rapid scientific progress and increasing complexity in development, manufacturing, and access pathways. Cellular therapies, refined immunotherapies, and targeted agents are reshaping clinical expectations, while supply chain and policy dynamics require heightened operational vigilance. Segmentation by disease subtype, therapy class, line of therapy, patient age group, care setting, and distribution channel illuminates where clinical innovation will most effectively translate into patient benefit and commercial viability.

Leaders who integrate translational excellence with resilient manufacturing, evidence strategies aligned to payer needs, and collaborative delivery models will be best positioned to realize the potential of recent scientific advances. Regional variation in infrastructure and reimbursement demands tailored approaches to development and market entry. Ultimately, the convergence of strong clinical evidence, pragmatic operational design, and strategic partnerships will determine whether innovations achieve broad, equitable impact across diverse healthcare systems.

This executive summary highlights the imperative for deliberate alignment across R&D, regulatory strategy, and commercialization planning so that promising therapies can move efficiently from concept to standard of care, delivering improved outcomes for patients living with hematological malignancies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hematological Malignancies Market, by Disease Type

  • 8.1. Leukemia
    • 8.1.1. Acute Lymphoblastic Leukemia
    • 8.1.2. Acute Myeloid Leukemia
    • 8.1.3. Chronic Lymphocytic Leukemia
    • 8.1.4. Chronic Myeloid Leukemia
  • 8.2. Lymphoma
    • 8.2.1. Hodgkin Lymphoma
      • 8.2.1.1. Classical
      • 8.2.1.2. Nodular Lymphocyte-Predominant
    • 8.2.2. Non-Hodgkin Lymphoma
      • 8.2.2.1. B-Cell
      • 8.2.2.2. T-Cell
  • 8.3. Multiple Myeloma
  • 8.4. Myelodysplastic Syndromes
    • 8.4.1. Refractory Anemia
    • 8.4.2. Refractory Anemia With Excess Blasts
    • 8.4.3. Refractory Anemia With Ring Sideroblasts
    • 8.4.4. Refractory Cytopenia With Multilineage Dysplasia
  • 8.5. Myeloproliferative Neoplasms
    • 8.5.1. Essential Thrombocythemia
    • 8.5.2. Myelofibrosis
    • 8.5.3. Polycythemia Vera

9. Hematological Malignancies Market, by Treatment Type

  • 9.1. Chemotherapy
  • 9.2. Immunotherapy
    • 9.2.1. CAR-T Cell Therapy
    • 9.2.2. Checkpoint Inhibitors
  • 9.3. Stem Cell Transplantation
    • 9.3.1. Allogeneic
    • 9.3.2. Autologous
  • 9.4. Targeted Therapy
    • 9.4.1. Immunomodulators
      • 9.4.1.1. Lenalidomide
      • 9.4.1.2. Thalidomide
    • 9.4.2. Monoclonal Antibodies
      • 9.4.2.1. Anti-CD20
      • 9.4.2.2. Anti-CD38
    • 9.4.3. Proteasome Inhibitors
      • 9.4.3.1. Bortezomib
      • 9.4.3.2. Carfilzomib
    • 9.4.4. Tyrosine Kinase Inhibitors
      • 9.4.4.1. BCR-ABL Inhibitors
      • 9.4.4.2. BTK Inhibitors

10. Hematological Malignancies Market, by Therapy Class

  • 10.1. Cellular Therapies
    • 10.1.1. CAR-T Cell Therapy
    • 10.1.2. Dendritic Cell Vaccines
  • 10.2. Immunomodulatory Drugs
    • 10.2.1. Pomalidomide
    • 10.2.2. Thalidomide
  • 10.3. Monoclonal Antibodies
    • 10.3.1. Anti-CD20
    • 10.3.2. Anti-CD38
  • 10.4. Proteasome Inhibitors
    • 10.4.1. Bortezomib
    • 10.4.2. Carfilzomib
  • 10.5. Small Molecule Inhibitors
    • 10.5.1. Tyrosine Kinase Inhibitors
    • 10.5.2. Venetoclax

11. Hematological Malignancies Market, by Line Of Therapy

  • 11.1. First-Line
  • 11.2. Maintenance Therapy
  • 11.3. Second-Line
  • 11.4. Third-Line And Beyond

12. Hematological Malignancies Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Hematological Malignancies Market, by End User

  • 13.1. Ambulatory Care Centers
  • 13.2. Hospitals
  • 13.3. Research Institutes
  • 13.4. Specialty Clinics

14. Hematological Malignancies Market, by Distribution Channel

  • 14.1. Direct Purchase
  • 14.2. Hospital Pharmacies
  • 14.3. Online Pharmacies
  • 14.4. Retail Pharmacies

15. Hematological Malignancies Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Hematological Malignancies Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Hematological Malignancies Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Hematological Malignancies Market

19. China Hematological Malignancies Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Adaptimmune Limited
  • 20.7. Adcendo ApS
  • 20.8. Amgen Inc.
  • 20.9. Artiva Biotherapeutics, Inc.
  • 20.10. Atara Biotherapeutics, Inc.
  • 20.11. Bristol-Myers Squibb Company
  • 20.12. Dren Bio, Inc.
  • 20.13. F. Hoffmann-La Roche AG
  • 20.14. Geron Corporation
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Harpoon Therapeutics, Inc.
  • 20.17. Immune-Onc Therapeutics, Inc.
  • 20.18. Interius BioTherapeutics, Inc.
  • 20.19. Johnson & Johnson Services, Inc.
  • 20.20. Karyopharm Therapeutics Inc.
  • 20.21. Kirilys Therapeutics, Inc.
  • 20.22. Kymera Therapeutics
  • 20.23. MEI Pharma, Inc.
  • 20.24. Merck & Co., Inc.
  • 20.25. Moleculin Biotech, Inc.
  • 20.26. NovalGen Ltd.
  • 20.27. Novartis AG
  • 20.28. Oncoternal
  • 20.29. Pfizer Inc.
  • 20.30. Prelude Therapeutics Incorporated
  • 20.31. Reverie Labs Inc.
  • 20.32. Sanofi S.A.
  • 20.33. Takeda Pharmaceutical Company Limited
  • 20.34. TG Therapeutics, Inc.
  • 20.35. Tvardi Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CLASSICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CLASSICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CLASSICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NODULAR LYMPHOCYTE-PREDOMINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NODULAR LYMPHOCYTE-PREDOMINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NODULAR LYMPHOCYTE-PREDOMINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY B-CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY B-CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY B-CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY T-CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY T-CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY T-CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH EXCESS BLASTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH EXCESS BLASTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH EXCESS BLASTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH RING SIDEROBLASTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH RING SIDEROBLASTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY ANEMIA WITH RING SIDEROBLASTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ESSENTIAL THROMBOCYTHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ESSENTIAL THROMBOCYTHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ESSENTIAL THROMBOCYTHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOFIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOFIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOFIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POLYCYTHEMIA VERA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POLYCYTHEMIA VERA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POLYCYTHEMIA VERA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BCR-ABL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BCR-ABL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BTK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BTK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BTK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ANTI-CD38, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY VENETOCLAX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY VENETOCLAX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY VENETOCLAX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THIRD-LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THIRD-LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 262. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 263. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 264. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 265. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 274. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 276. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MYELOPROLIFERATIVE NEOPLASMS, 2018-2032 (USD MILLION)
  • TABLE 278. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STEM CELL TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CELLULAR THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SMAL